Earnings
Organogenesis Cuts Revenue Forecast After Third-Quarter Sales Fall 70%
Management expects a slower fourth-quarter recovery, while cash and restricted cash stood at $26.9 million at September 30.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
Management expects a slower fourth-quarter recovery, while cash and restricted cash stood at $26.9 million at September 30.
SEC Filings
The optical-networking supplier returned to profit, but power access and construction issues are delaying its U.S. expansion.
SEC Filings
The largest slice matures in 2030, while €750 million carries interest tied to three-month EURIBOR.
SEC Filings
The optional program lets Fate set sale limits and pays Leerink up to 3% of gross proceeds.
Earnings
The security-software company bought CellGate to expand gate access, while nine-month operating cash flow rose to $167.6 million.
Earnings
Management is budgeting for sustainable Medicare ratings, while exceptional results could lift earnings above its recovery target.
SEC Filings
Takeda is running three late-stage elritercept trials, with payments tied to dosing the first patients.
SEC Filings
Royalties grew 71% over the trailing twelve months, while the chip-technology company forecasts $98.5 million to $99.5 million in annual sales.
Earnings
The rare-disease drug company expects more than $175 million in annual sales and an adjusted earnings margin of at least 40%.
SEC Filings
The biotech’s medicines remain in development, and its quarter-end balance is subject to completion of financial closing procedures.
Earnings
The temporary-space provider kept its adjusted earnings target unchanged as more deliveries and rental starts limited margin gains.
SEC Filings
The quarterly loss widened to $18.5 million, while Rezolute plans approval applications for one or potentially both indications in 2027.